Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

Journal of Urology

Volumn 197, Issue 5, 2017, Pages 1189-1199

  Chou, Roger ^a   Selph, Shelley ^a   Buckley, David I ^a   Fu, Rongwei ^a   Griffin, Jessica C ^a   Grusing, Sara ^a   Gore, John L ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

administration; BCG vaccine; interferons; intravesical; mitomycin; urinary bladder neoplasms

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; INTERFERON; MITOMYCIN; THIOTEPA; VALRUBICIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CLINICAL EFFECTIVENESS; CYSTECTOMY; HUMAN; MEDLINE; META ANALYSIS; MORTALITY RISK; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; BLADDER; BLADDER TUMOR; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; INTRAVESICAL DRUG ADMINISTRATION; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; SURGERY; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; CYSTECTOMY; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 85016053739     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.12.090     Document Type: Review

References (48)

1. 1 Siegel, R., Ma, J., Zou, Z., et al. Cancer statistics, 2014. CA Cancer J Clin, 64, 2014, 9.
2. 2 Kaufman, D.S., Shipley, W.U., Feldman, A.S., Bladder cancer. Lancet, 374, 2009, 239.
3. 3 American Cancer Society: Bladder Cancer; Survival rates for bladder cancer by stage, 2016. Available at http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-survival-rates.
4. 4 Chang SS, Boorjian SA, Chou R et al: Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline, 2016. Available at https://www.auanet.org/common/pdf/education/clinical-guidance/Non-Muscle-Invasive-Bladder-Cancer.pdf.
5. 5 Clark, P.E., Agarwal, N., Biagioli, M.C., et al. Bladder cancer. J Natl Compr Canc Netw, 11, 2013, 446.
6. 6 Chamie, K., Saigal, C.S., Lai, J., et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer, 117, 2011, 5392.
7. 7 Chou, R., Buckley, D., Fu, R., et al. Emerging Approaches to Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer. Comparative Effectiveness Reviews, No. 153. Prepared by the Pacific Northwest Evidence-based Practice Center. 2015, Agency for Healthcare Research and Quality, Rockville, Maryland.
8. 8 Agency for Healthcare Research and Quality: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. Rockville, Maryland: Agency for Healthcare Research and Quality 2014.
9. 9 Chou R, Gore J, Buckley D et al: Emerging approaches to diagnosis and treatment of non- muscle-invasive bladder cancer. PROSPERO 2014: CRD42014013284. Available at http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014013284.
10. 10 U.S. Preventive Services Task Force: U.S. Preventive Services Task Force Procedure Manual. AHRQ Publication No. 08-05118-EF, 2008.
11. 11 Fu, R., Gartlehner, G., Grant, M., et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol, 64, 2011, 1187.
12. 12 Higgins, J.P., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses. BMJ, 327, 2003, 557.
13. 13 Cornell, J.E., Mulrow, C.D., Localio, R., et al. Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med, 160, 2014, 267.
14. 14 Sterne, J.A., Sutton, A.J., Ioannidis, J.P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ, 343, 2011, d4002.
15. 15 Herr, H.W., Laudone, V.P., Badalament, R.A., et al. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol, 6, 1988, 1450.
16. 16 Rajala, P., Kaasinen, E., Raitanen, M., et al. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study—FinnBladder III long-term results. J Urol, 168, 2002, 981.
17. 17 Rajala, P., Liukkonen, T., Raitanen, M., et al. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study—Finnbladder III. J Urol, 161, 1999, 1133.
18. 18 Giannakopoulos, S., Gekas, A., Alivizatos, G., et al. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol, 82, 1998, 829.
19. 19 Portillo, J., Martin, B., Hernandez, R., et al. Results at 43 months’ follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology, 49, 1997, 187.
20. 20 Stavropoulos, N.E., Hastazeris, K., Filiadis, I., et al. Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer–results of a controlled prospective study. Scand J Urol Nephrol, 36, 2002, 218.
21. 21 Oddens, J.R., Sylvester, R.J., Brausi, M.A., et al. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol, 66, 2014, 694.
22. 22 Di Lorenzo, G., Perdonà, S., Damiano, R., et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer, 116, 2010, 1893.
23. 23 Addeo, R., Caraglia, M., Bellini, S., et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol, 28, 2010, 543.
24. 24 Pagano, F., Bassi, P., Milani, C., et al. Low dose BCG therapy in superficial bladder cancer: a clinicopathological perspective study. JB de Kernion, E Mazeman, (eds.) Immunotherapy of Urological Tumors, 1990, Churchill Livingstone, New York, 69–81.
25. 25 Melekos, M.D., Intravesical bacillus Calmette-Guérin prophylactic treatment for superficial bladder tumors: results of a controlled prospective study. Urol Int, 45, 1990, 137.
26. 26 Koga, H., Ozono, S., Tsushima, T., et al. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol, 17, 2010, 759.
27. 27 Pinsky, C.M., Camacho, F.J., Kerr, D., et al. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep, 69, 1985, 47.
28. 28 Ojea, A., Nogueira, J.L., Solsona, E., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol, 52, 2007, 1398.
29. 29 Witjes, W.P., Witjes, J.A., Oosterhof, G.O., et al. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Semin Urol Oncol, 14, 1996, 10.
30. 30 Di Stasi, S.M., Giannantoni, A., Stephen, R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol, 170, 2003, 777.
31. 31 Mangiarotti, B., Trinchieri, A., Del Nero, A., et al. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy. Arch Ital Urol Androl, 80, 2008, 167.
32. 32 DeBruyne, F.M.J., van der Meijden, P.M., Witjes, J.A., et al. Bacillus Calmette-Guérin versus mitomycin intravesical therapy in superficial bladder cancer: results of randomized trial after 21 months of follow-up. Urology, suppl., 40, 1992, 11.
33. 33 Krege, S., Giani, G., Meyer, R., et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol, 156, 1996, 962.
34. 34 Friedrich, M.G., Pichlmeier, U., Schwaibold, H., et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol, 52, 2007, 1123.
35. 35 Lundholm, C., Norlén, B.J., Ekman, P., et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol, 156, 1996, 372.
36. 36 Lamm, D.L., Blumenstein, B.A., Crawford, E.D., et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a Southwest Oncology Group study. Urol Oncol, 1, 1995, 119.
37. 37 Lamm, D.L., Blumenstein, B.A., Crissman, J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol, 163, 2000, 1124.
38. 38 Shelley, M.D., Kynaston, H., Court, J., et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int, 88, 2001, 209.
39. 39 Han, R.F., Pan, J.G., Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology, 67, 2006, 1216.
40. 40 Sylvester, R.J., Oosterlinck, W., Holmang, S., et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?. Eur Urol, 69, 2016, 231.
41. 41 Abern, M.R., Owusu, R.A., Anderson, M.R., et al. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw, 11, 2013, 477.
42. 42 Perlis, N., Zlotta, A.R., Beyene, J., et al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol, 64, 2013, 421.
43. 43 Malmström, P.U., Sylvester, R.J., Crawford, D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol, 56, 2009, 247.
44. 44 Sylvester, R.J., Oosterlinck, W., Witjes, J.A., The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol, 53, 2008, 709.
45. 45 Onishi, T., Sasaki, T., Hoshina, A., et al. Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor. Anticancer Res, 31, 2011, 1471.
46. 46 Arends, T.J., Nativ, O., Maffezzini, M., et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol, 69, 2016, 1046.
47. 47 Committee for Establishment of the Clinical Practice Guidelines for the Management of Bladder Cancer and the Japanese Urological Association. Evidence-based clinical practice guidelines for bladder cancer (summary - JUA 2009 Edition). Int J Urol, 17, 2010, 102.
48. 48 Babjuk, M., Böhle, A., Burger, E., et al. Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS). 2015, European Association of Urology, Arnhem, The Netherlands.